• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.

作者信息

van Besien K W, de Lima M, Giralt S A, Moore D F, Khouri I F, Rondón G, Mehra R, Andersson B S, Dyer C, Cleary K, Przepiorka D, Gajewski J L, Champlin R E

机构信息

Department of Hematology, The University of Texas MD Anderson Cancer Center, Houston 77030, USA.

出版信息

Bone Marrow Transplant. 1997 May;19(10):977-82. doi: 10.1038/sj.bmt.1700781.

DOI:10.1038/sj.bmt.1700781
PMID:9169641
Abstract

Donor lymphocyte infusions, by virtue of a graft-versus-tumor effect, have been shown to induce remissions in leukemia that recurs after allogeneic bone marrow transplantation. Similar effects have been postulated to contribute to the decreased recurrence rate observed after allogeneic transplantation in non-Hodgkin's lymphoma. This lower recurrence rate may be due to a variety of other mechanisms. We aimed to evaluate the role of graft-versus-lymphoma effects in patients in whom lymphomas recur after allogeneic transplantation. At the time of recurrence, immunosuppressive therapy was withheld. Patients with non-responding disease received an infusion of donor lymphocytes. Patients were observed for response and graft-versus-host disease. Disease in four of nine patients responded to withdrawal of immunosuppressive therapy. A minor response was observed in one of three recipients of donor lymphocyte infusions. Responses were observed among two patients with follicular lymphoma, one with large cell lymphoma and one with lymphoblastic lymphoma. A minor response was observed in a patient with prolymphocytic leukemia/lymphoma. We conclude that withdrawal of immunosuppressive therapy and donor lymphocyte infusion can induce durable remissions in patients with recurrent lymphoma after allogeneic transplantation.

摘要

相似文献

1
Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect.
Bone Marrow Transplant. 1997 May;19(10):977-82. doi: 10.1038/sj.bmt.1700781.
2
Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.异基因干细胞移植后复发的惰性淋巴瘤中供体淋巴细胞输注的移植物抗淋巴瘤效应
Bone Marrow Transplant. 2003 Dec;32(12):1159-63. doi: 10.1038/sj.bmt.1704290.
3
Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.使用供体淋巴细胞进行异基因细胞介导的免疫疗法,以预防接受异基因骨髓移植治疗血液系统恶性肿瘤的患者复发。
Clin Transpl. 1996:281-90.
4
High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma.惰性非霍奇金淋巴瘤异基因干细胞移植后对供体淋巴细胞输注的高反应率。
Biol Blood Marrow Transplant. 2008 Jan;14(1):50-8. doi: 10.1016/j.bbmt.2007.04.013.
5
Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.异基因骨髓移植治疗复发难治性霍奇金淋巴瘤和非霍奇金淋巴瘤。
Bone Marrow Transplant. 1997 Sep;20(5):369-74. doi: 10.1038/sj.bmt.1700904.
6
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.异基因反应性作为血液系统恶性肿瘤治疗的治疗原则。非清髓性预处理的异基因造血细胞移植的临床和免疫学方面的研究。
Dan Med Bull. 2007 May;54(2):112-39.
7
Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients.用噻替派、白消安和环磷酰胺进行预处理后,对预后不良的复发或难治性非霍奇金淋巴瘤进行异基因移植:44例连续患者的经验
Biol Blood Marrow Transplant. 1997 Aug;3(3):150-6.
8
Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.
Bone Marrow Transplant. 1996 Jul;18(1):257-9.
9
Graft-versus-leukemia effects from donor lymphocyte infusion after nonmyeloablative allogeneic bone marrow transplantation in mice.小鼠非清髓性异基因骨髓移植后供体淋巴细胞输注的移植物抗白血病效应
Chin Med J (Engl). 2005 Mar 20;118(6):474-9.
10
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.减低强度异基因造血干细胞移植后早期供体植入的建立,以增强移植物抗淋巴瘤效应治疗难治性淋巴瘤。
Biol Blood Marrow Transplant. 2003 Mar;9(3):162-9. doi: 10.1053/bbmt.2003.50008.

引用本文的文献

1
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center.新型细胞疗法时代B细胞淋巴瘤的异基因造血细胞移植:来自加拿大一家三级中心的经验
Curr Oncol. 2025 May 20;32(5):285. doi: 10.3390/curroncol32050285.
2
High-Dose Chemotherapy and Autologous or Allogeneic Transplantation in Aggressive B-Cell Lymphoma-Is There Still a Role?大剂量化疗联合自体或异基因移植治疗侵袭性 B 细胞淋巴瘤:是否仍有一席之地?
Cells. 2024 Oct 27;13(21):1780. doi: 10.3390/cells13211780.
3
Allogeneic Hematopoietic Stem Cell Transplant for Diffuse Large B-Cell Lymphoma: Evolving Role in the Era of CAR T-Cell Therapy.
异基因造血干细胞移植治疗弥漫性大 B 细胞淋巴瘤:在 CAR-T 细胞治疗时代的不断演变。
Curr Oncol Rep. 2023 Jun;25(6):599-607. doi: 10.1007/s11912-023-01403-7. Epub 2023 Mar 28.
4
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy.新药和CAR-T细胞疗法时代套细胞淋巴瘤的异基因干细胞移植
Cancers (Basel). 2021 Jan 14;13(2):291. doi: 10.3390/cancers13020291.
5
Cellular Immunotherapy in Lymphoma: Beyond CART Cells.淋巴瘤中的细胞免疫疗法:超越嵌合抗原受体T细胞疗法
Curr Treat Options Oncol. 2020 Feb 11;21(3):21. doi: 10.1007/s11864-020-0709-3.
6
Drug therapy for double-hit lymphoma.双打击淋巴瘤的药物治疗
Drugs Context. 2019 Dec 2;8. doi: 10.7573/dic.2019-8-1. eCollection 2019.
7
Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma.异基因造血细胞移植为转化滤泡性淋巴瘤患者提供了治愈的机会。
J Cancer Res Clin Oncol. 2018 Jun;144(6):1173-1183. doi: 10.1007/s00432-018-2633-5. Epub 2018 Apr 5.
8
Gene Delivery Approaches for Mesenchymal Stem Cell Therapy: Strategies to Increase Efficiency and Specificity.基因传递方法在间充质干细胞治疗中的应用:提高效率和特异性的策略。
Stem Cell Rev Rep. 2017 Dec;13(6):725-740. doi: 10.1007/s12015-017-9760-2.
9
Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma.低强度异基因或自体移植治疗复发3级滤泡性淋巴瘤的长期生存结果
Bone Marrow Transplant. 2016 Jan;51(1):58-66. doi: 10.1038/bmt.2015.223. Epub 2015 Oct 5.
10
Non-myeloablative allogeneic hematopoietic transplantation for patients with hematologic malignancies: 9-year single-centre experience.非清髓性异基因造血干细胞移植治疗血液系统恶性肿瘤:9 年单中心经验。
Curr Oncol. 2014 Jun;21(3):e434-40. doi: 10.3747/co.21.1846.